₹1,316.9
▼ -15.32 -1.15%
17 Jul 2026
NSE Listed
Global Health Limited (MEDANTA)
20-day avg volume: 1.5L shares
- Company is almost debt-free.
- Stock trades at a high P/E of 249.
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹861 Cr | ₹957 Cr | ₹943 Cr | ₹931 Cr | ₹1,031 Cr | ₹1,099 Cr | ₹1,121 Cr | ₹1,159 Cr |
| EBITDA | ₹162 Cr | ₹197 Cr | ₹205 Cr | ₹198 Cr | ₹222 Cr | ₹201 Cr | ₹178 Cr | ₹214 Cr |
| Net Profit | ₹106 Cr | ₹131 Cr | ₹143 Cr | ₹101 Cr | ₹159 Cr | ₹158 Cr | ₹95 Cr | ₹144 Cr |
| EPS | — | — | — | — | — | — | — | — |
| Metric | Mar 2018 | Mar 2019 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,392 Cr | ₹1,506 Cr | ₹1,478 Cr | ₹2,206 Cr | ₹2,759 Cr | ₹3,350 Cr | ₹3,771 Cr | ₹4,410 Cr |
| EBITDA | ₹83 Cr | ₹116 Cr | ₹100 Cr | ₹360 Cr | ₹527 Cr | ₹701 Cr | ₹762 Cr | ₹0 Cr |
| Net Profit | ₹33 Cr | ₹51 Cr | ₹29 Cr | ₹196 Cr | ₹326 Cr | ₹478 Cr | ₹481 Cr | ₹556 Cr |
| EPS | 6.52 | 2.04 | 1.14 | 7.77 | 12.57 | 17.8 | 17.92 | — |
| Metric | Mar 2018 | Mar 2019 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | ₹1,984 Cr | ₹2,430 Cr | ₹2,694 Cr | ₹3,146 Cr | ₹4,116 Cr | ₹4,304 Cr | ₹4,766 Cr |
| Total Liabilities | ₹767 Cr | ₹1,135 Cr | ₹1,312 Cr | ₹1,530 Cr | ₹1,688 Cr | ₹1,398 Cr | ₹1,379 Cr |
| Equity | ₹1,217 Cr | ₹1,295 Cr | ₹1,382 Cr | ₹1,616 Cr | ₹2,428 Cr | ₹2,906 Cr | ₹3,388 Cr |
| Total Debt | — | — | — | — | — | — | — |
| Metric | Mar 2018 | Mar 2019 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Operating | ₹116 Cr | ₹233 Cr | ₹258 Cr | ₹409 Cr | ₹751 Cr | ₹790 Cr | ₹788 Cr |
| Investing | ₹-69 Cr | ₹-249 Cr | ₹-239 Cr | ₹-421 Cr | ₹-342 Cr | ₹-441 Cr | ₹-721 Cr |
| Financing | ₹9 Cr | ₹97 Cr | ₹-81 Cr | ₹160 Cr | ₹346 Cr | ₹-514 Cr | ₹-97 Cr |
| Free Cash Flow | ₹116 Cr | ₹233 Cr | ₹258 Cr | ₹409 Cr | ₹751 Cr | ₹790 Cr | ₹788 Cr |
Healthcare · Healthcare
Global Health Limited, together with its subsidiaries, provides healthcare services in India. The company offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and gynaeoncology, paediatric care, obstetrics, emergency, ENT, head and neck surgery, internal medicine, respiratory and sleep medicine, peripheral vascular and endovascular sciences, endocrinology and diabetes, rheumatology and immunology, radiology and imaging, ophthalmology, critical care, dermatology, dentistry, and dietetics and nutrition, as well as plastic, aesthetic, and reconstructive surgery. It also provides second opinion, lab tests and diagnostics, homecare and elder care services, telemedicine and air ambulance services, and e-ICU services, and health plans checkup. In addition, the company is involved in trading of pharmacy and other medical consumables; and medical and healthcare education activities. The company operates a network of hospitals under the Medanta brand. Global Health Limited was incorporated in 2004 and is based in Gurugram, India.
www.medanta.org ↗As of 2026-03-31
Quarterly — figures in %. Latest 12 quarters.
| Period | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 33.1% | 33.1% | 33.1% | 33% | 33% | 33% | 33% | 33% | 33% | 33% | 33% | 33% |
| FIIs | 10.6% | 10.7% | 11.4% | 12.1% | 12.9% | 12.2% | 12.5% | 11.8% | 11.5% | 11.4% | 10.5% | 10.1% |
| DIIs | 10.8% | 10.9% | 9.7% | 10.3% | 10.6% | 11.1% | 10.5% | 11.9% | 12.2% | 13% | 14% | 14.8% |
| Public | 45.5% | 45.3% | 45.9% | 44.6% | 43.4% | 43.6% | 44% | 43.3% | 43.2% | 42.6% | 42.5% | 42.1% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 1,09,798 | 1,16,627 | 1,24,775 | 1,66,253 | 1,55,307 | 1,49,722 | 1,48,633 | 1,54,688 | 1,56,372 | 1,55,806 | 1,51,241 | 1,47,390 |
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
| Name | Category | Stake | Shares |
|---|---|---|---|
| Naresh Trehan | Shareholding of Promoter and Promoter Group | 33% | 8.87 Cr |
| Dunearn Investments (mauritius) Pte Ltd | Public Shareholding | 14.8% | 3.99 Cr |
| Sunil Sachdeva | Public Shareholding | 10.8% | 2.90 Cr |
| Rj Corp Limited | Public Shareholding | 6.6% | 1.77 Cr |
| Invesco India Aggressive Hybrid Fund | Public Shareholding | 5.1% | 1.36 Cr |
| Kotak Contra Fund | Public Shareholding | 3.3% | 89,78,504 |
| Government Pension Fund Global | Public Shareholding | 3.2% | 86,01,606 |
| Canara Robeco Mutual Fund A/c Canara Robeco Conser | Public Shareholding | 1.9% | 50,08,045 |
| Polaris Healthcare Investments Pte Ltd | Public Shareholding | 1.9% | 50,00,000 |
| Uti-flexi Cap Fund | Public Shareholding | 1.8% | 47,08,623 |
| Novo Holdings A/s | Public Shareholding | 1% | 27,16,376 |
| Madhu Trehan | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Naveen Trehan | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Neena Malhotra | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Shyel Trehan | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Shonan Trehan | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Aroon Purie | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Naresh Trehan Huf | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Rkm Family Trust | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Naresh Trehan Family Trust | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Medanta Institute Of Education And Research | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Insaniyat | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Medanta Foundation - Poor And Needy Patients Welfare Trust | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Ntm Family Trust | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Sm Family Trust | Shareholding of Promoter and Promoter Group | 0% | 0 |
| Holder | Pledged Shares | % of Holding | As of |
|---|---|---|---|
| Naresh Trehan | 0 | 0% | 2026-03-31 |
| Madhu Trehan | 0 | 0% | 2026-03-31 |
| Naveen Trehan | 0 | 0% | 2026-03-31 |
| Neena Malhotra | 0 | 0% | 2026-03-31 |
| Shyel Trehan | 0 | 0% | 2026-03-31 |
| Shonan Trehan | 0 | 0% | 2026-03-31 |
| Aroon Purie | 0 | 0% | 2026-03-31 |
| Naresh Trehan Huf | 0 | 0% | 2026-03-31 |
| Rkm Family Trust | 0 | 0% | 2026-03-31 |
| Naresh Trehan Family Trust | 0 | 0% | 2026-03-31 |
| Medanta Institute Of Education And Research | 0 | 0% | 2026-03-31 |
| Insaniyat | 0 | 0% | 2026-03-31 |
| Name | Designation | Year |
|---|---|---|
| Naresh Kumar Trehan | Chairman / Executive Director / Managing Director | 2025 |
| Pankaj Prakash Sahni | Executive Director & CEO | 2025 |
| Hari S Bhartia | Independent Non Exe. Director | 2025 |
| Praveen Mahajan | Independent Non Exe. Director | 2025 |
| Rajan Bharti Mittal | Independent Non Exe. Director | 2025 |
| RAVI GUPTA | Independent Non Exe. Director | 2025 |
| RAVI KANT JAIPURIA | Non Executive Director / Nominee | 2025 |
| Sunil Sachdeva | Non-Exec & Non-Independent Dir | 2025 |
| Vikram Singh Mehta | Independent Non Exe. Director | 2025 |
| RAHUL RANJAN | Company Sec. & Compli. Officer | 2025 |
| Segment | Revenue | Share |
|---|---|---|
| Healthcare services | ₹0 Cr | — |
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹2 | 234 | 54 | 54 |
| Type | Date | Value | Remark |
|---|---|---|---|
| dividend | 2025-08-22 | ₹0.5 (25%) | Final |
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 92 | 0 | 0 | 37 | 17 | 146 |
| 2025 | 55 | 0 | 0 | 0 | 0 | 55 |
| 2025 | 15 | 0 | 0 | 0 | 2 | 16 |
1 disclosure(s)
📍 Medanta-Mediclinic, E-18 Defence Colony, New Delhi, New Delhi, 110024
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search